--- title: "Novo Nordisk UBT251 shows impressive phase II clinical data in China, with a weight loss effect of nearly 20%" description: "Novo Nordisk's authorized drug UBT251 shows impressive Phase II clinical data in China: a maximum weight loss of 19.7% after 24 weeks of treatment (only 2% for the placebo), and the company stated it " type: "news" locale: "en" url: "https://longbridge.com/en/news/276728466.md" published_at: "2026-02-24T11:58:39.000Z" --- # Novo Nordisk UBT251 shows impressive phase II clinical data in China, with a weight loss effect of nearly 20% > Novo Nordisk's authorized drug UBT251 shows impressive Phase II clinical data in China: a maximum weight loss of 19.7% after 24 weeks of treatment (only 2% for the placebo), and the company stated it is "very encouraged." However, affected by negative news regarding Cagrisema, the stock price still fell over 4%. Novo Nordisk has paid a $200 million upfront payment, with the total deal potentially reaching $2 billion, aimed at finding new growth points in the weight loss drug market Novo Nordisk's experimental weight loss drug UBT251 has achieved significant weight loss results in its Phase II clinical trial in China, providing strong support for the company to seek new growth engines in the competitive weight loss drug market. **According to a report from Novo Nordisk's Chinese partner, United Pharmaceutical, patients with obesity and overweight in China experienced a maximum weight loss of 19.7% after 24 weeks of taking the drug,** while patients taking a placebo averaged only a 2% weight loss. Martin Holst Lange, head of research and development at Novo Nordisk, stated in a press release that the company is "very encouraged" by the data from this trial in China. Based on this positive interim result, United Pharmaceutical will initiate a Phase III clinical trial in China, while Novo Nordisk plans to announce the topline data from its ongoing global early trials in 2027. Despite the impressive data from the new drug, Novo Nordisk's recent performance in the capital market remains under pressure. On Tuesday, affected by negative news regarding its next-generation weight loss drug Cagrisema and multiple analysts downgrading their ratings, Novo Nordisk's stock price fell by as much as 4.4% during trading. Over the past year, the company's stock price has cumulatively dropped by more than 60%.## **Triple Agonist Shows Higher Potential** The clinical data released reveals the potential of multi-target drugs in the weight loss field. A total of 205 patients participated in this Phase II trial, who were randomly assigned to receive doses of 2mg, 4mg, or 6mg of the drug or a placebo. The current trial results are based on the estimated adherence of all patients to the medication as planned, and specific details on whether any patients discontinued treatment have not yet been provided. UBT251 is a triple agonist that can simultaneously mimic three hormones involved in metabolism: GLP-1, GIP, and glucagon. This multi-faceted mechanism of action means it may have stronger efficacy than Novo Nordisk's current blockbuster weight loss drug Wegovy, which only targets GLP-1. ## **Billion-Dollar Deal with Heavy Investment** This promising drug is an important external investment by Novo Nordisk to maintain its dominant position in the obesity market. Last year, the Danish pharmaceutical company paid a $200 million upfront fee to obtain the development rights for UBT251 outside of China. **As the clinical process advances and potential commercialization materializes, the total value of this licensing deal could reach up to $2 billion.** Against the backdrop of investors calling for the company to adjust its strategy and respond to the latest R&D setbacks, the progress of UBT251 is expected to boost market confidence in Novo Nordisk's pipeline for future efforts ### Related Stocks - [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md) - [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md) - [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md) - [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md) - [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md) - [600110.CN - NUODE](https://longbridge.com/en/quote/600110.CN.md) - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md) - [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md) - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | “彻底失望”！德银首次下调诺和诺德评级 | 诺和诺德关键减肥药 CagriSema 临床不及礼来，引发罕见降级潮：德银五年来首降评级，摩根大通下调至 “中性” 并砍销售预期 63%。股价周一暴跌 16%，目前仅 37% 分析师给予 “买入” 评级。市场焦点转向 ziltivekima | [Link](https://longbridge.com/en/news/276726950.md) | | “彻底失望”！德银首次下调诺和诺德评级 | 德意志银行首次下调诺和诺德股票评级至 “持有”，因其减肥药 CagriSema 在临床试验中表现不佳，导致市场抛售，股价暴跌 16%。摩根大通也下调评级并大幅削减销售预期，华尔街对该股的看涨比例降至数年最低，显示出对诺和诺德中期前景的悲观情 | [Link](https://longbridge.com/en/news/276727300.md) | | 诺和诺德明年大幅下调减肥神药在美售价，降幅最高 50% | 诺和诺德宣布将司美格鲁肽系列药物美国月标价统一降至 675 美元，降幅最高 50%，明年 1 月生效，旨在应对礼来竞争与市场压力。消息公布后美股盘前跌 3%，本周因新药数据不佳已累跌 19%。降价主要惠及高免赔额计划参保人，与 Medica | [Link](https://longbridge.com/en/news/276745048.md) | | 美股夜盘异动：诺和诺德夜盘跌 3.68%，减肥药试验失利与目标价下调双重打击市场信心 | 诺和诺德公司夜盘跌 3.68%；礼来夜盘跌 0.24%，成交额达到 2.19 百万美元；辉瑞夜盘跌 0.15%，成交额达到 57.95 万美元；如瑞迪博士夜盘跌 1.02%，成交额达到 16.6 万美元。 | [Link](https://longbridge.com/en/news/276701324.md) | | 期权热点｜周一 NVO 大跌 16%，部分看跌期权飙升 6775% | 美东时间 02 月 23 日，诺和诺德公司期权总成交 316590 张，看涨期权占比 57%，看跌期权占比 42%。 | [Link](https://longbridge.com/en/news/276681569.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.